TARGETED THERAPY IN COMPLEX TREATMENT OF RENAL CANCER PATIENTS WITH BRAIN METASTASES


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The frequency of metastatic brain lesions in patients with renal cancer (RC) is 2-11%, it is constantly growing and represents one of the major causes of failure in the treatment of these patients. Surgery and radiation therapy, including radiosurgical treatment, should be considered as the optimal treatment of patients with RC with brain metastases. In recent years, systemic drug therapy plays an increa-sing role in the treatment of patients with progression of brain tumor. However, there are no precise pharmacokinetic data on medications, approved for the treatment of disseminated RC, with respect to their concentration in the central nervous system in humans when used in therapeutic doses. Based on a literature review and results of own research, it can be concluded that none of the new targeted therapies has not demonstrated significant advantages over other ones in the treatment of RC patients with brain metastases. The greatest efficacy data are available for the treatment with sunitinib and sorafenib. In the case of progression of brain tumor, drug treatment should be discussed in each situation individually and in accordance with standard approaches to the treatment of patients with advanced RC.

全文:

受限制的访问

作者简介

D. Naskhletashvili

FSBI «RORC n.a. N.N. Blokhin» of RMH

Email: nas-david@yandex.ru
PhD, Senior Scientist at the Neurosurgical (Oncological) Department Moscow

参考

  1. Choueiri T.K., Duh M.S., Clement J., Brick A.J., Rogers M.J., Kwabi C., Shah K., Percy A.G., Antras L., Jayawant S.S., Chen K., Wang S.T., Luka A., Neary M.P., McDermott D., Oh W.K. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 2009
  2. Culine S., Bekradda M., Kramar A., Rey A., Escudier B., Droz J.P. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer. 1998;83:2548-53.
  3. Dalhaung A., Haukland E., Nieder C. Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib. World J. Surg. Oncol. 2010;8:36.
  4. Elfiky A.A., Cho D.C., McDermott D.F., Rosenberg J.E., Fortner B., Antras L., Chen K., Sheng Duh M., Jayawant S.S., Oh W.K., Atkins M.B., Choueiri T.K. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear cell renal carcinoma. Urol. Oncol. 2011;29(6):756-63.
  5. Escudier B, Bellmut J., Negrier S., Bajetta E., Melichar B., Bracarda S., Ravaud A., Golding S., Jethwa S., Sneller V. Phase III trial of bevacizumab plus interferon alpha-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 2010;28:2144-50.
  6. Escudier B, Eisen T., Stadler W.M., Szczylik C., Oudard S., Staehler M., Negrier S., Chevreau C., Desai A.A., Rolland F., Demkow T., Hutson T.E., Gore M., Anderson S., Hofilena G., Shan M., Pena C., Lathia C., Bukowski R.M. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cell cancer global evaluation trial. J. Clin. Oncol. 2009;27:3312-18.
  7. Feldman D.R., Baum M.S., Ginsberg M.S., Hassoun H., Flombaum C.D., Velasco S., Fischer P., Ronnen E., Ishill N., Patil S., Motzer R.J. Phase 1 trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. Genitourinary Cancer. 2009;27:1432-39.
  8. Gleave M.E., Elhilali M., Fradet Y., Davis I., Venner P., Saad F., Klotz L.H., Moore M.J., Paton V., Bajamonde A. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. New Engl. J. Med. 1998;338:1265-71.
  9. Gore M.E., Hariharan S., Porta C., Bracarda S., Hawkins R., Bjarnason G.A., Oudard S., Lee S.H., Carteni G., Nieto A., Yuan J., Szczylik C. Sunitinib in metastatic renal carcinoma patients with brain metastases. Cancer. 2011;117:501-9.
  10. Guirgis L.M., Yang J.C., White D.E., Steinberg S.M., Liewehr D.J., Rosenberg S.A., Schwartzentruber D.J. Safety and efficacy of high dose IL-2 therapy in patients with brain metastasis. J. Immunother. 2002;25:82-7.
  11. Haznedar J., Patyna S., Bello C.L., Peng G.W., Speed W., Yu X., Zhang Q., Sukbuntherng J., Sweeny D.J., Antonian L., Wu E.Y. Single and multiple dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother.Pharmacol. 2009;64:691-706.
  12. Helgason H.H., Mallo H.A., Droogendijk H., Haanen J.G., van der Veldt A.A., van den Eertwegh A.J., Boven E. Brain metastases in patients with renal cell cancer new targeted treatment. J. Clin. Oncol. 2008;26:152-54.
  13. Hu S., Chen Z., Franke R., Orwick S., Zhao M., Rudek M.A., Sparreboom A., Baker S.D. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin. Cancer Res. 2009;15:6062-69.
  14. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermottD.,BodrogiI., KovacevicZ.,Lesovoy V., Schmidt-Wolf I.G., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R.J. Temsirolimus, interferon alpha, or both for advanced renal cell carcinoma. New Engl. J. Med.2007;456:2271-81.
  15. Iwamoto F.M., Lamborn K.R., Robins I.H., Mehta M.P., Chang S.M., Butowski N.A., Deangelis L.M., Abrey L.E., Zhang W.T., Prados M.D., Fine H.A. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010;12:855-61.
  16. Kim A., McCully C., Cruz R., Cole D.E., Fox E., Balis F.M., Widemann B.C. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. Invest New Drugs. 2012;30(2):524-
  17. [Epub 2010 Nov 12].
  18. Kirchner H., Strumberg D., Bahl A., Overkamp F. Patient based strategy for systemic treatment of metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 2010;10:585-96.
  19. Kuhn J.G., Chang S.M., Wen P.Y., Cloughesy T.F., Greenberg H., Schiff D., Conrad C., Fink K.L., Robins H.I., Mehta M., DeAngelis L., Raizer J., Hess K., Lamborn K.R., Dancey J., Prados M.D. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin. Cancer Res. 2007;13:7401-406.
  20. Lagas J.S., van Waterschoot R.A., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel A.H. Breast cancer resistance protein and p-glycoprotein limit sorafenib brain accumulation. Molec. Cancer Ther. 2010;9:319-26.
  21. Larkin J., Gore M. Is advanced renal cell carcinoma becoming a chronic disease? Lancet. 2010;376:574-75.
  22. Lukas R.V., Chmura S., Nicholas M.K. Management of central nervous system metastases from renal cancer. Emerg. Cancer Therap. 2011;2:157-68.
  23. Massard C.,Zonierek J.,Gross-Goupil M.,Fizazi K., Szczylik C., Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann. Oncol. 2010;21:1027-31.
  24. Medioni J.,Cojocarasu O., Belcaceres J.L.,Halimi P., Oudard S. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann. Oncol. 2007;18:1282-83.
  25. Motzker R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., Figlin R.A. Sunitinib versus interferon alpha in metastatic renal cell carcinoma. New Engl. J. Med. 2007; 356:115-24.
  26. Muacevic A., Siebels M., Tonn J.C., Wowra B. Treatment of brain metastases in renal cell carcinoma: radiotherapy, radiosurgery, or surgery? World J. Urol. 2005;23:180-84.
  27. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Gr nwald V., Thompson J.A., Figlin R.A., Hollaender N., Kay A., Ravaud A. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256-65.
  28. Muldoon L.L.,Soussain C.,Jahnke K.,Johanson C., Siegal T., Smith Q.R., Hall W.A., Hynynen K., Senter P.D., Peereboom D.M., Neuwelt E.A. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 2007;25:2295-305.
  29. Murata J.I., Sawamura Y., Terasaka S., Saito H., Abe H. Complete response of a large brain metastasis of renal cell cancer to interferonalpha: case report. Surg. Neurol. 1999;51:289-91.
  30. Nicholas M.K., Lukas R. Immunologic privilege and the brain. In: Arnason BG, ed. NeuroImmune Biology: The Brain and Host Defense, Vol. 9. London, 2010. Р. 169-81.
  31. O'Reilly T., McSheehy P., Kawai R., Kretz O., McMahon L., Brueggen J., Bruelisauer A., Gschwind H.P., Allegrini P.R., Lane H.A. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother. Pharmacol. 2010;54:625-39.
  32. Saitoh H. Distant metastases from renal carcinoma. Cancer. 1988;48:1487-91.
  33. Samlowski W.E., Majer M., Boucher K.M., Shrieve A.F., Dechet C., Jensen R.L., Shrieve D.C. Multidisciplinary treatment of brain metasta-ses derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer. 2008;113:2539-48.
  34. Shuch B., LaRochelle J.C., Klatte T., Riggs S.B., Liu W., Kabbinavar F.F., Pantuck A.J., Belldegrun A.S. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008;113;1641-48.
  35. Shukla S., Robey R.W., Bates S.E., Ambudkar S.V. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters p-glycoprotein (ABCB1) and ABCG2. Drug.Metab. Dispos. 2009;37:359-65.
  36. Sperduto P.W, Chao S.T.,Sneed P.K., Luo X.,Suh J., Roberge D., Bhatt A., Jensen A.W., Brown P.D., Shih H., Kirkpatrick J., Schwer A., Gaspar L.E., Fiveash J.B., Chiang V., Knisely J., Sperduto C.M., Mehta M. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metas-tases: a multi-institutional analysis of 4259 patients. Int. J. Radiat. Oncol. Biol. Phys. 2010; 77:655-61.
  37. Stadler W.M., Figlin R.A., McDermott D.F., Dutcher J.P., Knox J.J., Miller W.H. Jr, Hainsworth J.D., Henderson C.A., George J.R., Hajdenberg J., Kindwall-Keller T.L., Ernstoff M.S., Drabkin H.A., Curti B.D., Chu L., Ryan C.W., Hotte S.J., Xia C., Cupit L., Bukowski R.M. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116:1272-79.
  38. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C.H., Salman P., Gladkov O.A., Kavina A., Zarba J.J., Chen M., McCann L., Pandite L., Roychowdhury D.F., Hawkins R.E. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 2010;28:1061-68.
  39. Thibault F., Billemont B., Rixe O. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy. J. Neurooncol. 2008;86:243-44.
  40. Ranze O., Hoffman E., Distelrath A., Hoeffkes H.G. Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib. Onkologie. 2007;30:450-51.
  41. ValcamonicoF.,FerrariV.,AmorosoV.,RangoniG., Simoncini E., Marpicati P., Vassalli L., Grisanti S., Marini G. Long lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J. Neurooncol. 2009;91:47-50.
  42. Vogl U.M., Bojic M., Lamm W., Frischer J.M., Pichelmayer O., Kramer G., Haitel A., Kitz K., Harmankaya K., Zielinski C.C., Schmidinger M. Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. BMC Cancer. 2010;10:480.
  43. Vredenburgh J.J., Cloughesy T., Samant M., Prados M., Wen P.Y., Mikkelsen T., Schiff D., Abrey L.E., Yung W.K., Paleologos N., Nicholas M.K., Jensen R., Das A., Friedman H.S. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010;15:1329-34.
  44. YamanakaK.,Gohji K., HaraI., Gotoh A., Takechi Y., Yamada Y., Taguchi I., Tamada H., Okada H., Arakawa S., Kamidono S. Clinical study of renal cell carcinoma with brain metastasis. Int. J. Urol. 1998;5:124-28.
  45. Zeng H., Li X., Yao J., Zhu Y., Liu J., Yang Y., Qiang W. Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib. Urol. Int. 2009;83:482-85.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2016
##common.cookie##